Key result
This review discusses the management of cardiac disease during pregnancy and the safety of cardiac medications for the mother and fetus.
This review provides an overview of the safety and management of cardiac medications in pregnant women with heart disease.
Supports cautious medication selection in pregnant cardiac patients; leaves open need for prospective safety trials.
Cardiovascular disease is the most encountered cause of maternal death during pregnancy in the western world and an increase in maternal mortality due to cardiac causes has been observed. More women with congenital or acquired heart disease have the desire to become pregnant. Pregnancy is known to impose a major hemodynamic burden and also has impacts on the coagulation system. The risk of developing complications is clearly increased as compared with the normal population. For optimal management, it is crucial to have information on the effects of cardiac medications on the fetus. The focus of this article is to discuss the management of cardiac disease in pregnancy, as well as the known safety of cardiac medications for the mother and/or fetus.
No takes yet. Share an insight, caveat, or question.
Bosch et al. (2015) conducted a review in Cardiac disease in pregnancy. Cardiac medications was evaluated. This review discusses the management of cardiac disease during pregnancy and the safety of cardiac medications for the mother and fetus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: